SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 114.70K | 114.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 114.70K | 114.70K |
| Cost of Revenue | 48.27M | 39.09M | 33.35M | 30.58M | 29.44M |
| Gross Profit | -48.27M | -39.09M | -33.35M | -30.46M | -29.32M |
| SG&A Expenses | 23.56M | 19.09M | 15.60M | 12.73M | 12.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.82M | 58.18M | 48.95M | 43.31M | 41.94M |
| Operating Income | -71.82M | -58.18M | -48.95M | -43.19M | -41.82M |
| Income Before Tax | -12.78M | -398.10K | 13.27M | 18.74M | -37.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.78 | -0.40 | 13.27 | 18.74 | -37.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.78M | -398.10K | 13.27M | 18.74M | -37.05M |
| EBIT | -71.82M | -58.18M | -48.95M | -43.19M | -41.82M |
| EBITDA | -68.71M | -55.12M | -45.87M | -40.09M | -38.52M |
| EPS Basic | -0.19 | -1.00 | -1.21 | -2.37 | -3.99 |
| Normalized Basic EPS | 2.05 | 1.54 | 1.42 | 0.87 | -2.49 |
| EPS Diluted | -1.10 | -1.90 | -2.11 | -3.09 | -4.00 |
| Normalized Diluted EPS | -0.25 | -0.76 | -0.88 | -1.43 | -2.49 |
| Average Basic Shares Outstanding | 191.97M | 121.51M | 77.24M | 38.54M | 37.14M |
| Average Diluted Shares Outstanding | 259.17M | 188.71M | 144.45M | 105.74M | 37.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |